Clinical trial
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
NCT00372437 · Mirati Therapeutics Inc., Industry · Completed
Key facts
| NCT number | NCT00372437 |
|---|---|
| Title | A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine |
| Official title | A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine |
| Lead sponsor | Mirati Therapeutics Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | MGCD0103, Gemcitabine |
| Enrollment | 47 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 7, 2006 |
| Last update posted | Jul 1, 2015 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: